Beverly Hills, California. May 15, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin’s shareholders for $38,000,000. Nordicus will be issuing 38 million restricted common shares in an all-stock transaction to the selling shareholders.
With Nordicus becoming Orocidin’s single largest shareholder, Henrik Rouf, CEO of Nordicus, and Henrik Keller, Director of Nordicus, will both join Orocidin’s Board of Directors.
Henrik Rouf stated, “We are thrilled to become the largest shareholder of Orocidin, a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. With the global market for periodontal disease therapeutics estimated to cross $1.3 billion in 2029, there is an urgent, unmet need for new and improved treatment options for periodontitis, which is why we made this timely investment.”
Allan Wehnert, CEO and founder of Orocidin, added, “I am honored that Nordicus decided to acquire almost all of Orocidin, as they share our vision and see the huge untapped potential for our innovative therapeutic agent, QR-01, a remarkable product that is specifically designed to meet the key challenge of treating periodontitis and belongs to a unique class of host defense peptides characterized by functions such as antimicrobial, and immunomodulatory roles.
In addition to antimicrobial activity, QR-01 also participates in the activation of specific immune responses in patients. Apart from antimicrobial activity, QR-01 exerts its protective effects by its antibiofilm activities,
In summary QR-01 is a key product in restraining the progression of periodontitis.
About Nordicus Partners Corporation
Nordicus Partners Corporation and its Denmark-based financial consulting company, specializing in providing Nordic and U.S. Life Sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. The company’s core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities, such as: business valuations, growth strategies, attracting capital for businesses and company acquisitions and sales. For more information about Nordicus, please visit: www.nordicuspartners.com
Forward-Looking Statements
The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Current Report on Form 8-K relating to the reverse acquisition and related transactions which was filed with the SEC on March 1, 2023 and its quarterly report on Form 10-Q for the fiscal period ended December 31, 2023. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
For further information contact:
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com
Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.
Elizabeth Addonizio is an experienced finance professional with twenty-five years of business and leadership experience. She is the founder of Fair Winds Capital LLC, AMN LLC, and GEDI LLC, through which she has spent the past decade investing, along with families and entrepreneurs, in U.S.-based, sector-agnostic, early-stage venture investments that prioritize impact and environmental, social, and good governance (ESG) principles by investing in companies’ Pre-seed to C-round capital raises. She has also served as a fractional CFO for many companies in diverse sectors.
Prior to her venture investing and CFO work, from 2012 to 2016, Ms. Addonizio was a founding managing director and investment professional at Cranemere, an international investment holding company and private equity firm structured to invest with a commitment to sustainability and ESG principles, along with other families, in middle market private companies (~$200mm-$500mm in enterprise value). While at Cranemere she sourced and evaluated dozens of investment opportunities, serving on the firm’s Investment Committee, and overseeing due diligence, financing, and other acquisition-related activities. Prior to joining Cranemere, from 2006 to 2012, Ms. Addonizio worked at Morgan Stanley in the Investment Banking and Corporate M&A and Strategy Divisions, advising on over $25 billion of mergers and acquisitions, leveraged finance, and equity transactions.
In addition to her work in finance, since 2004, Ms. Addonizio has served as an intelligence officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. Previously, she was Executive Officer of 110+-person Navy Reserve Joint Intelligence Operations Center Europe (JIOCEUR) Analytic Center Molesworth 0366 (located at Joint Reserve Intelligence Support Element Sheridan, Fort Sheridan, IL). Prior to this position, she served as the board-selected Executive Officer of 75-person ONI Navy Reserve Nimitz Unit at Fort Dix, NJ. She was also the Officer in Charge (OIC) of a twenty-eight-person Naval Criminal Investigative Service (NCIS) Unit based in New London, CT. Board-selected to hold this position, she was one of only three to have command of a unit at her rank in the Navy Reserve Intelligence Community, the first woman to ever serve in this NCIS unit, and by extension, the unit’s first female OIC. During her twenty years in the U.S. Navy, she has led numerous teams in support of JIOCEUR, ONI, NCIS, and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the Commander of U.S. Central Command, General David Petraeus.
Earlier in her career, Ms. Addonizio was elected to serve two terms as the 9th Ward Alderwoman in New Haven, Connecticut, serving as the Vice Chair of the Finance Committee with legislative oversight of the city’s $450 million annual budget. As a Henry Luce Scholar in China, she taught economics at Peking University and worked on China’s accession to the World Trade Organization at the World Bank Resident Mission. She has also worked in the U.S. National Security Council and in the Office of the U.S. Trade Representative. She holds a Ph.D. from Yale University, a M.P.A. from Princeton University, a B.A. from Bucknell University, and was a Fulbright Scholar in El Salvador. Ms. Addonizio is currently a member of the Association for Corporate Growth and the Alliance of Merger and Acquisitions Advisers. She is also a Council on Foreign Relations Life Member, a NationSwell Council Member, a Truman National Security Project Fellow, and a Yale World Fellow.